Tg Therapeutics (TGTX) Change in Accured Expenses (2011 - 2026)

Tg Therapeutics' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $34.0 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 47.81% year-over-year to $34.0 million; the TTM figure through Mar 2026 stood at -$33.5 million (down 139.47% YoY), while the FY2025 annual figure was -$2.4 million, down 110.43% from the prior year.
• Change in Accured Expenses was $34.0 million for Q1 2026 at Tg Therapeutics, up from -$56.3 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $65.2 million in Q1 2025 to a low of -$67.5 million in Q2 2025.
• Historically, Change in Accured Expenses has averaged $3.3 million across 5 years, with a median of $2.4 million in 2022.
• Biggest YoY gain for Change in Accured Expenses was 2103.66% in 2023; the steepest drop was 1596.82% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $874000.0 in 2022, then soared by 193.36% to $2.6 million in 2023, then soared by 679.52% to $20.0 million in 2024, then slumped by 381.44% to -$56.3 million in 2025, then soared by 160.47% to $34.0 million in 2026.
• The last three Change in Accured Expenses figures came in at $34.0 million (Q1 2026), -$56.3 million (Q4 2025), and $56.2 million (Q3 2025), per Business Quant data.